ICD-10 Coding Reference for Meningioma with Pharmaceutical Adverse Effect Context
Legacy of General Health and Science Information
The legacy of general health and science information has long served as a foundational resource for public understanding of disease. This heritage is built on the careful translation of complex medical terminology into accessible knowledge, enabling individuals to recognize symptoms, understand diagnostic categories, and engage with the healthcare system. Within this broad educational framework, specific disease classifications—such as those found in standardized coding systems—have provided a common language for clinicians and researchers alike. This shared vocabulary is essential for tracking epidemiological trends, allocating resources, and ensuring continuity of care across different medical specialties. However, the utility of this general health information extends beyond the clinical encounter. As the focus shifts from describing a condition in isolation to understanding its origins, the same coding frameworks become instrumental in a different investigative context. The transition from a purely educational or diagnostic perspective to one concerned with causation introduces a critical new dimension: the patient’s history of exposure. In this light, a diagnosis is not merely a label for a set of symptoms but also a potential signal that warrants a systematic inquiry into the individual’s past environment. This pivot moves the discussion from the general principles of disease to the specific, actionable question of whether a particular pharmaceutical agent or occupational setting may have contributed to the observed health outcome. The coding reference thus becomes a starting point for a targeted risk assessment.
Bridge to Pharmaceutical Adverse Effect Coding
Building on the legacy of general health information, this coding reference specifically addresses the intersection of pharmaceutical exposure and meningioma diagnosis. The query links pharmaceutical adverse health effects to the ICD-10 code for meningioma, emphasizing the need for precise documentation of both the neoplasm and the causative agent. This section bridges the general educational framework to the specialized coding context, highlighting how standardized codes capture the drug-disease relationship. For coding professionals, the primary diagnosis is the meningioma, coded according to histologic behavior and anatomic site, while the adverse effect of the pharmaceutical is captured using external cause codes from the T36–T50 range. This dual coding approach ensures accurate representation of the clinical scenario, supporting epidemiological tracking and patient safety initiatives.
Clinical Presentation and Diagnosis of Meningioma
Meningiomas are typically slow-growing neoplasms arising from the arachnoid cap cells of the meninges. Clinical presentation depends on tumor location and size; common symptoms include new-onset seizures, focal neurological deficits (e.g., hemiparesis, cranial nerve palsies), headaches, and signs of increased intracranial pressure. Diagnosis is usually established through contrast-enhanced magnetic resonance imaging (MRI), which reveals a dural-based, homogeneously enhancing mass. Definitive diagnosis requires histopathological examination of resected tismedical context, with grading per World Health Organization (WHO) criteria (grade I, II, or III). The ICD-10-CM code for benign meningioma is D32.0 (meninges of brain) or D32.1 (meninges of spinal cord); malignant meningioma is coded under C70.0 (cerebral meninges) or C70.1 (spinal meninges). For coding purposes, the specific code depends on the histologic behavior and anatomic site documented in the pathology report.
Pharmaceutical Pharmacology and Reported Adverse Effects
The query specifically links pharmaceutical exposure to the development of meningioma. Among the most well-documented pharmaceutical triggers are progestin-based therapies, particularly cyproterone acetate (CPA) and certain hormonal contraceptives. CPA is a steroidal anti-androgen with progestogenic activity, used for conditions such as hirsutism, prostate cancer, and gender-affirming therapy. Pharmacologically, CPA binds to progesterone receptors (PR) and androgen receptors, exerting suppressive effects on gonadotropin secretion. Long-term use of CPA at high doses (e.g., 50–100 mg/day) has been associated with an increased incidence of meningioma, as reported in pharmacovigilance databases and case-control studies. Similarly, the progestin nomegestrol acetate and chlormadinone acetate have been linked to meningioma growth in case reports. The mechanism is believed to involve PR-mediated mitogenic signaling, as meningiomas frequently express high levels of progesterone receptors. Other pharmaceutical classes, such as growth hormone (GH) therapy, have also been investigated; however, the evidence for GH is less robust and primarily limited to case reports of tumor recurrence rather than de novo induction.
Mechanistic Pathways Linking Pharmaceutical to Meningioma
The mechanistic pathway for progestin-associated meningioma is grounded in hormonal receptor biology. Meningioma cells express progesterone receptors in approximately 70–80% of cases, particularly in grade I tumors. Progestins like CPA act as potent agonists at these receptors, promoting cell proliferation through downstream signaling cascades, including activation of the mitogen-activated protein kinase (MAPK) pathway and upregulation of cyclin D1. Additionally, progestins may inhibit apoptosis via Bcl-2 family modulation. The dose-response relationship is supported by clinical observations: high cumulative doses of CPA (e.g., >1,500 mg total) and prolonged exposure (≥3–5 years) correlate with increased meningioma risk. Tumor regression has been documented after discontinuation of CPA, further supporting a causal, hormone-dependent mechanism. For other pharmaceuticals, such as immunosuppressants (e.g., cyclosporine) or antivirals, the mechanistic link is less defined; however, chronic immune modulation or direct oncogenic viral interactions (e.g., with cytomegalovirus) have been hypothesized but not conclusively proven.
Safety-Communication Context Regarding Pharmaceutical and Meningioma
Regulatory safety communications have highlighted the risk of meningioma with certain progestins. For example, the European Medicines Agency (EMA) has issued warnings for cyproterone acetate-containing products, recommending restricted use and periodic MRI surveillance for patients on long-term therapy. The U.S. Food and Drug Administration (FDA) has similarly updated labeling for CPA (marketed as Androcur in some countries, though not FDA-approved in the U.S.) and for progestin-only contraceptives, noting postmarketing reports of meningioma. These communications emphasize that the absolute risk remains low, but the risk increases with cumulative dose and duration. For affected patients, the clinical interpretation is that any new neurological symptom—such as persistent headache, visual disturbance, or seizure—during or after progestin therapy warrants neuroimaging. Coding professionals should document the pharmaceutical exposure using an external cause code (e.g., T45.0X5A for adverse effect of antineoplastic drugs, or more specifically, T38.9X5A for adverse effect of other systemic hormonal preparations) in addition to the meningioma diagnosis code, to capture the drug-adverse effect relationship.
CodingReference-Focused Clinical Interpretation for Affected Patients
For affected patients, the coding reference must integrate both the neoplasm and the pharmaceutical cause. The primary diagnosis is the meningioma, coded as D32.0 (benign cerebral meninges) or C70.0 (malignant cerebral meninges), depending on histology. The adverse effect of the pharmaceutical is coded using the T36–T50 range for poisoning by drugs, medicaments, and biological substances, with a fifth or sixth character indicating adverse effect. For example, T38.9X5A (adverse effect of other systemic hormonal preparations, initial encounter) is appropriate for CPA. Additionally, a Z-code (e.g., Z79.899, other long-term current drug therapy) may be used to indicate ongoing pharmaceutical use. If the patient has discontinued the drug, a personal history code (Z92.21, personal history of antineoplastic chemotherapy) or a code for personal history of other drug therapy (Z92.29) may apply. The timeline between exposure and outcome is critical: meningiomas typically develop after 3–10 years of continuous progestin use, and regression can occur within months of cessation. Therefore, coders should document the duration of therapy and the temporal relationship in the medical record to support the causal link.
Timeline Between Exposure and Documented Health Outcomes
The latency period for pharmaceutical-associated meningioma varies by agent. For CPA, the median duration of exposure before diagnosis is approximately 5–7 years, with a cumulative dose threshold of 1,500–2,000 mg. In contrast, for progestin contraceptives, the risk appears lower and may require longer exposure, though data are limited. After drug cessation, tumor stabilization or regression is observed in up to 30–50% of cases within 6–12 months, as documented in longitudinal imaging studies. For coding and risk stratification, the timeline is essential: if the patient was exposed for less than 1 year, the causal association is weak; if exposure exceeded 3 years, the association is more plausible. This temporal information should be captured in the clinical note and reflected in the coding, as it influences both treatment decisions (e.g., surgical resection vs. observation) and medicolegal documentation.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.
ICD-10-CM reference — D32.0
| Field | Value |
|---|---|
| Code | D32.0 |
| Descriptor | Benign neoplasm of cerebral meninges |
| Billable | Yes |
| Includes | Meningioma (benign) of brain |
| Excludes1 | Malignant meningioma (C70.0) |
| Excludes2 | Meningioma of spinal cord (D32.1) |
| Adverse effect code | T38.9X5A |
| Long-term drug use | Z79.899 |
| Personal history of drug therapy | Z92.29 |
Frequently Asked Questions
What is the ICD-10 code for benign meningioma?
The ICD-10-CM code for benign meningioma is D32.0 for meninges of brain and D32.1 for meninges of spinal cord. These codes are used when the tumor is histologically confirmed as benign (WHO grade I).
How do you code an adverse effect of a pharmaceutical like cyproterone acetate?
For adverse effects of pharmaceuticals, use codes from the T36–T50 range. For cyproterone acetate, a systemic hormonal preparation, the code T38.9X5A (adverse effect of other systemic hormonal preparations, initial encounter) is appropriate. This should be used in addition to the meningioma diagnosis code.
Does submitting information create an medical context-client relationship?
No. Submission requests an initial records screening only and does not create an medical context-client relationship.
References
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.